Sermorelin acetate | GHRH(1-29) | CAS#114466-38-5 | GHRH analog

MedKoo Cat#: 326656 | Name: Sermorelin acetate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sermorelin, also known as GHRH (1-29), is a growth hormone-releasing hormone (GHRH) analogue used as a diagnostic agent. It is a 29-amino acid polypeptide representing the 1–29 fragment from endogenous human GHRH, and is thought to be the shortest fully functional fragment of GHRH.[1] It is used as a diagnostic agent to assess growth hormone (GH) secretion. Sermorelin use is also hypothesized to improve deep rapid eye movement sleep.

Chemical Structure

Sermorelin acetate

CAS#114466-38-5 (acetate)

Theoretical Analysis

MedKoo Cat#: 326656

Name: Sermorelin acetate

CAS#: 114466-38-5 (acetate)

Chemical Formula: C151H250N44O44S

Exact Mass: 0.0000

Molecular Weight: 3417.99

Elemental Analysis: C, 53.06; H, 7.37; N, 18.03; O, 20.60; S, 0.94

Price and Availability

Size	Price	Availability
1g	USD 4,250.00	2 weeks
2g	USD 6,950.00	2 weeks
5g	USD 12,850.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

114466-38-5 (acetate); 86168-78-7 (free base)

Synonym

GHRH (1-29); Sermorelin acetate; trade name: Geref.

IUPAC/Chemical Name

H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2

InChi Key

InChi Code

SMILES Code

CC[C@@H]([C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CCCNC(N)=N)=O)CO)=O)CCSC)=O)[C@H](CC)C)=O)CC(O)=O)=O)CCC(N)=O)=O)CC(C)C)=O)CC(C)C)=O)CCCCN)=O)CCCNC(N)=N)=O)C)=O)CO)=O)CC(C)C)=O)CCC(N)=O)=O)=O)CC(C)C)=O)C(C)C)=O)CCCCN)=O)CCCNC(N)=N)=O)Cc1ccc(O)cc1)=O)CO)=O)CC(N)=O)=O)[C@H](O)C)=O)Cc2ccccc2)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](Cc3ccc(O)cc3)N)=O)C)=O)CC(O)=O)=O)C)=O)C.CC(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 3,417.99 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Knoop A, Thomas A, Fichant E, Delahaut P, Schänzer W, Thevis M. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Anal Bioanal Chem. 2016 May;408(12):3145-53. doi: 10.1007/s00216-016-9377-3. Epub 2016 Feb 15. PubMed PMID: 26879649; PubMed Central PMCID: PMC4830873. 2: Venhuis BJ, Keizers PH, Klausmann R, Hegger I. Operation resistance: A snapshot of falsified antibiotics and biopharmaceutical injectables in Europe. Drug Test Anal. 2016 Mar;8(3-4):398-401. doi: 10.1002/dta.1888. Epub 2015 Oct 12. PubMed PMID: 26456392. 3: Thomas A, Walpurgis K, Tretzel L, Brinkkötter P, Fichant E, Delahaut P, Schänzer W, Thevis M. Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS. Drug Test Anal. 2015 Nov-Dec;7(11-12):990-8. doi: 10.1002/dta.1868. Epub 2015 Sep 18. PubMed PMID: 26382721. 4: Bagno LL, Kanashiro-Takeuchi RM, Suncion VY, Golpanian S, Karantalis V, Wolf A, Wang B, Premer C, Balkan W, Rodriguez J, Valdes D, Rosado M, Block NL, Goldstein P, Morales A, Cai RZ, Sha W, Schally AV, Hare JM. Growth hormone-releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy. J Am Heart Assoc. 2015 Mar 31;4(4). pii: e001464. doi: 10.1161/JAHA.114.001464. PubMed PMID: 25827134; PubMed Central PMCID: PMC4579962. 5: Kanashiro-Takeuchi RM, Szalontay L, Schally AV, Takeuchi LM, Popovics P, Jaszberenyi M, Vidaurre I, Zarandi M, Cai RZ, Block NL, Hare JM, Rick FG. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6(12):9728-39. PubMed PMID: 25797248; PubMed Central PMCID: PMC4496393. 6: Catanuto P, Tashiro J, Rick FG, Sanchez P, Solorzano CC, Glassberg MK, Block NL, Lew JI, Elliot SJ, Schally AV. Expression of Receptors for Pituitary-Type Growth Hormone-Releasing Hormone (pGHRH-R) in Human Papillary Thyroid Cancer Cells: Effects of GHRH Antagonists on Matrix Metalloproteinase-2. Horm Cancer. 2015 Jun;6(2-3):100-6. doi: 10.1007/s12672-015-0217-2. Epub 2015 Mar 10. PubMed PMID: 25752763. 7: Qin YJ, Chan SO, Chong KK, Li BF, Ng TK, Yip YW, Chen H, Zhang M, Block NL, Cheung HS, Schally AV, Pang CP. Antagonist of GH-releasing hormone receptors alleviates experimental ocular inflammation. Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):18303-8. doi: 10.1073/pnas.1421815112. Epub 2014 Dec 8. PubMed PMID: 25489106; PubMed Central PMCID: PMC4280596. 8: Szalontay L, Schally AV, Popovics P, Vidaurre I, Krishan A, Zarandi M, Cai RZ, Klukovits A, Block NL, Rick FG. Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function. Cell Cycle. 2014;13(17):2790-7. doi: 10.4161/15384101.2015.945879. PubMed PMID: 25486366; PubMed Central PMCID: PMC4615138. 9: Muñoz-Moreno L, Arenas MI, Carmena MJ, Schally AV, Prieto JC, Bajo AM. Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models. Invest New Drugs. 2014 Oct;32(5):871-82. doi: 10.1007/s10637-014-0131-4. Epub 2014 Jul 8. PubMed PMID: 25000999. 10: Nair D, Ramesh V, Li RC, Schally AV, Gozal D. Growth hormone releasing hormone (GHRH) signaling modulates intermittent hypoxia-induced oxidative stress and cognitive deficits in mouse. J Neurochem. 2013 Nov;127(4):531-40. doi: 10.1111/jnc.12360. Epub 2013 Jul 19. PubMed PMID: 23815362; PubMed Central PMCID: PMC3851434. 11: Seitz S, Rick FG, Schally AV, Treszl A, Hohla F, Szalontay L, Zarandi M, Ortmann O, Engel JB, Buchholz S. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers. Oncol Rep. 2013 Jul;30(1):413-8. doi: 10.3892/or.2013.2435. Epub 2013 Apr 29. PubMed PMID: 23624870. 12: Rick FG, Schally AV, Block NL, Abi-Chaker A, Krishan A, Szalontay L. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia. Prostate. 2013 Jun;73(8):873-83. doi: 10.1002/pros.22633. Epub 2012 Dec 31. PubMed PMID: 23280565. 13: Ziegler CG, Ullrich M, Schally AV, Bergmann R, Pietzsch J, Gebauer L, Gondek K, Qin N, Pacak K, Ehrhart-Bornstein M, Eisenhofer G, Bornstein SR. Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells. Mol Cell Endocrinol. 2013 May 22;371(1-2):189-94. doi: 10.1016/j.mce.2012.12.011. Epub 2012 Dec 23. PubMed PMID: 23267837; PubMed Central PMCID: PMC3690370. 14: Rick FG, Seitz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Buchholz S, Block NL, Hohla F. GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. Cell Cycle. 2012 Nov 15;11(22):4203-10. doi: 10.4161/cc.22498. Epub 2012 Oct 24. PubMed PMID: 23095641; PubMed Central PMCID: PMC3524216. 15: Xu Y, Jiang YF, Wu B. New agonist- and antagonist-based treatment approaches for advanced prostate cancer. J Int Med Res. 2012;40(4):1217-26. Review. PubMed PMID: 22971474. 16: Perez R, Schally AV, Vidaurre I, Rincon R, Block NL, Rick FG. Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers. Oncotarget. 2012 Sep;3(9):988-97. PubMed PMID: 22941871; PubMed Central PMCID: PMC3660064. 17: Siejka A, Barabutis N, Schally AV. GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitro. Peptides. 2012 Sep;37(1):63-8. doi: 10.1016/j.peptides.2012.07.010. Epub 2012 Jul 20. PubMed PMID: 22819774. 18: Muñoz-Moreno L, Arenas MI, Schally AV, Fernández-Martínez AB, Zarka E, González-Santander M, Carmena MJ, Vacas E, Prieto JC, Bajo AM. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer. Int J Cancer. 2013 Feb 15;132(4):755-65. doi: 10.1002/ijc.27716. Epub 2012 Jul 27. PubMed PMID: 22777643. 19: Telegdy G, Schally AV. Involvement of neurotransmitters in the action of growth hormone-releasing hormone antagonist on passive avoidance learning. Behav Brain Res. 2012 Aug 1;233(2):326-30. doi: 10.1016/j.bbr.2012.05.030. Epub 2012 May 26. PubMed PMID: 22640814. 20: Wang T, Hai J, Chen X, Peng H, Zhang H, Li L, Zhang Q. Inhibition of GHRH aggravated acetaminophen-induced acute mice liver injury through GH/IGF-I axis. Endocr J. 2012;59(7):579-87. Epub 2012 May 26. PubMed PMID: 22572547.

View History

Sertindole